Demand for GLP-1 medications for weight loss is rising rapidly in Europe, especially in the United Kingdom, Germany and France.
In the UK, researchers have estimated that approximately 1.6 million adults used weight-loss medications such as Wegovy and Mounjaro during 2024/2025, showing significant demand.
In France, from June 2026, the country will be the first in Europe to begin covering the costs of weight-loss medication through the public healthcare system, which is expected to make the medicine more accessible to citizens.
Globally, the market is expected to more than double to $190bn in 2035, driven by increased adoption in the United States, Europe and other regions. This is according to Healthcare Dive, a US news platform covering the healthcare sector, including pharmaceutical trends, policy and innovation.
The development shows that obesity medication is becoming a global phenomenon … and that discussions about long-term health are relevant throughout the global community, reports Gustav H. Gram (pictured), CEO of Pila Pharma.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
